Provided by Tiger Trade Technology Pte. Ltd.

Cidara Therapeutics

221.38
0.0000
Volume:- -
Turnover:- -
Market Cap:6.96B
PE:-19.73
High:221.38
Open:221.38
Low:221.38
Close:221.38
52wk High:221.42
52wk Low:15.22
Shares:31.44M
Float Shares:24.87M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.2200
EPS(LYR):-26.7460
ROE:-68.70%
ROA:-29.35%
PB:16.48
PE(LYR):-8.28

Loading ...

Cidara Therapeutics announces presentation on CD388 at ESWI Conference

TIPRANKS
·
Oct 23, 2025

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025

GlobeNewswire
·
Oct 23, 2025

Cidara Therapeutics Price Target Maintained With a $150.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 22, 2025

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025

GlobeNewswire
·
Oct 21, 2025

Cidara Therapeutics Initiated at Overweight by Morgan Stanley

Dow Jones
·
Oct 16, 2025

Morgan Stanley Initiates Cidara Therapeutics at Overweight With $190 Price Target

MT Newswires Live
·
Oct 16, 2025

Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market

TIPRANKS
·
Oct 16, 2025

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

GlobeNewswire
·
Oct 13, 2025

Cidara Therapeutics (CDTX) Is Up 10.8% After FDA Grants Breakthrough Therapy Designation to CD388

Simply Wall St.
·
Oct 11, 2025

Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive'

Benzinga_recent_news
·
Oct 11, 2025

Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage

Benzinga_recent_news
·
Oct 10, 2025

Cidara Therapeutics Initiated at Overweight by JP Morgan

Dow Jones
·
Oct 10, 2025

U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity

Reuters
·
Oct 10, 2025

Cidara Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Target Price $200

THOMSON REUTERS
·
Oct 10, 2025

Why Cidara Therapeutics Stock Crushed It Today

Motley Fool
·
Oct 10, 2025

HC Wainwright Raises Cidara Therapeutics' Price Target to $150 From $110, Buy Rating Kept

MT Newswires Live
·
Oct 09, 2025

Cidara Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 09, 2025

Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating

TIPRANKS
·
Oct 09, 2025

Cidara Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $150 From $110

THOMSON REUTERS
·
Oct 09, 2025

Cidara Therapeutics Shares up 6.5% After FDA's 'Breakthrough Therapy' Tag for Flu Prevention Drug

THOMSON REUTERS
·
Oct 09, 2025